Strategy
Business Development
Innovative partnerships, licensing opportunities, and a flexible approach to market expansion.
03
Business Development
Avalon’s business development initiatives are a key driver of its strategic growth and sustainable success. Through innovative partnerships, licensing opportunities both locally and internationally, and a flexible market expansion approach, Avalon continues to strengthen its leadership in the pharmaceutical and healthcare sector.
Portfolio Expansion Agreements
The company leverages these agreements to access the latest technologies and expand its product range. Through collaboration with global partners, Avalon integrates advanced technological processes into its modern manufacturing facilities. This approach enables the company to deliver innovative products that address diverse therapeutic needs, strengthening its competitive capabilities.
Licensing Rights of Avalon’s Trusted Products to External Partners
Avalon’s strong pharmaceutical formulations attract companies seeking to reduce risk and accelerate market entry, leveraging its expertise in manufacturing and regulatory affairs. Avalon supports its partners in efficiently launching its trusted products into new markets. Additionally, the production of selected products under private label arrangements contributes to partners’ growth, while ensuring the highest standards of quality and safety.
Excellence in Contract Manufacturing
Avalon has expanded its manufacturing capabilities to become a trusted partner in contract manufacturing (production under formal agreements). Through its flexible and scalable production capacity, the company provides solutions for both pilot-scale production and large-scale commercial manufacturing. In addition, Avalon collaborates with other contract manufacturers to meet demand for products beyond its existing production lines, ensuring that all partnerships align with its strict quality and compliance standards.
Strategic Alliances for Long-Term Growth
Avalon’s collaborative and integrated business approach reflects its commitment to building strategic alliances that drive growth. The company actively pursues long-term partnerships founded on mutual trust, transparency, and shared objectives. By integrating resources and strengthening relationships based on mutual interests, Avalon creates sustainable value for its partners, fostering innovation and enhancing its competitiveness at both local and global levels.
During the year, Avalon successfully completed the development and SFDA registration procedures for 12 new products, supporting the expansion of its growth pipeline. In parallel, the company entered into an agreement to develop and commercialize a generic version of (Wegovy) an anti-obesity product within the GLP-1 class of medications—expanding its presence in advanced obesity treatments. Additionally, Avalon finalized two agreements in the oncology segment, reinforcing the expansion of its specialized product portfolio.
The Business Development team continued collaborating with approved development partners to advance oncology products and complex injectable formulations, while also focusing on selected opportunities in the aesthetics segment, including microneedling technology .
A Structured Partnership Approach
Avalon’s partnership strategy is designed to ensure effective and value-driven collaboration:
Search
Conducting in-depth analytical studies to select partners with complementary expertise and aligned strategic objectives.
Selection
Conducting a thorough evaluation of potential partners to ensure alignment with Avalon’s values and strategic objectives.
Initiation
Launching collaborative initiatives with clearly defined objectives to achieve mutual growth.
Assurance
Implementing ongoing measures to maintain the integrity and effectiveness of the partnership.
Growth Vision
Avalon’s business development efforts align with its “ACE” strategy Accelerate, Catalyze ,Expand. These initiatives include:
- Expanding market reach through strategic alliances and innovative licensing agreements.
- Enhancing manufacturing capabilities to meet the growing demand in the global healthcare sector.
- Maintaining Avalon’s position as a leading player in key therapeutic categories.
Through its dynamic and forward-looking approach, Avalon continues to set new standards in delivering innovative healthcare solutions, while ensuring sustainable growth for its partners and stakeholders.
2025
Operational Performance Assessment
In 2025, Avalon’s business development efforts played a pivotal role in executing its strategic roadmap, aligned with its ambitious ACE framework (Accelerate, Catalyze, Expand). The focus was on innovation, expanding strategic alliances, and entering new markets.
Key achievements include:
Strengthening Strategic Alliances and External Licensing Agreements
Avalon expanded its collaboration with leading retailers, transitioning from a supplier role to a manufacturer. This enabled the production of private label products and strengthened Avalon’s market presence. These partnerships reinforced Avalon’s position in the Saudi market, demonstrating its ability to deliver specialized solutions that effectively meet customer needs.
Market Expansion
The company achieved significant growth in export markets, with successful relaunches in Kuwait and the UAE. These initiatives helped establish Avalon as a regional leader, leveraging support from the Saudi Export Development Authority to access new markets.
Innovation-Driven Product Line
Avalon’s R&D efforts produced advanced products supported by strategic technology transfer agreements. These partnerships aim to localize advanced pharmaceutical technologies and strengthen Avalon’s presence in specialized sectors such as oncology and ophthalmology treatments.
Looking ahead, Avalon’s Business Development team is preparing to build on these achievements by focusing on exclusive product launches, expanding regional partnerships, and aligning with Saudi Vision 2030 objectives. This includes strengthening collaborations with local content supporters to localize production and exploring high-value therapeutic sectors to meet the growing demand for healthcare services.